Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC004 PK Interaction with Itraconazole or Rifampicin in Healthy Adults
NCT06619951Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eratrectinib in solid tumor (2 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Curve From Time Zero to Last Quantifiable Concentration. Started Sep 2024; status: completed.
02
Drugs
eratrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06619951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619951.